Pavan Tenneti Venkata, MD
Hematology & Oncology · Sun City, AZNPI 1578851572
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $489 of the $589 with a category attached, or 83.0%. 11 manufacturers reported payments, led by Bristol Myers Squibb at 26.9% of the total. Reporting peaked in 2019 at $275 and has fallen 77.7% since, to $61 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AZ, where the typical reported total is $6,870.
Across 16 payments — averaging $36.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$158
- Incyte Corporation$117
- Seagen Inc.$100
- Aimmune Therapeutics, Inc.$61
- Novartis$37
- Pharmaessentia USA Corporation$24
- plus $92 from 5 others
What the payments were for
- Food & beverage$48983%
- Education$10017%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 2 | $158 |
| Incyte Corporation | 1 | $117 |
| Seagen Inc. | 1 | $100 |
| Aimmune Therapeutics, Inc. | 2 | $61 |
| Novartis | 2 | $37 |
| Pharmaessentia USA Corporation | 1 | $24 |
| Lilly USA, LLC | 1 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $20 |
| Genentech USA, Inc. | 3 | $19 |
| Sanofi | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$589 in reported general payments places this provider in the 20th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 61 | $67,544 |
| Prochlorperazine Maleate | 36 | $1,299 |
| Ondansetron Hcl | 42 | $768 |
| Hydroxyurea | 34 | $688 |
| Oxycodone Hcl | 29 | $573 |
| Letrozole | 11 | $411 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 15 | $205 |
| Dexamethasone | 11 | $103 |
| Warfarin Sodium | 14 | $90 |
| Potassium Chloride | 28 | $64 |
| Prednisone | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Sun City
- Sujith KalmadiChandler$1.4M
- Jeffrey SchriberScottsdale$715K
- Javier MunozPhoenix$638K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Sumit MadanGilbert$422K
- Christopher ChenTucson$370K
- Rachna ShroffTucson$250K
- Govardhanan NagaiahGoodyear$222K
- Yousef ZakhariaScottsdale$214K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.